JP2018532737A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018532737A5 JP2018532737A5 JP2018519702A JP2018519702A JP2018532737A5 JP 2018532737 A5 JP2018532737 A5 JP 2018532737A5 JP 2018519702 A JP2018519702 A JP 2018519702A JP 2018519702 A JP2018519702 A JP 2018519702A JP 2018532737 A5 JP2018532737 A5 JP 2018532737A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- substituted
- ring members
- substituents
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021132047A JP7254127B2 (ja) | 2015-10-21 | 2021-08-13 | ベンゾラクタム化合物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1518676.0 | 2015-10-21 | ||
| GBGB1518676.0A GB201518676D0 (en) | 2015-10-21 | 2015-10-21 | Benzolactam compounds |
| GB1611351.6 | 2016-06-30 | ||
| GBGB1611351.6A GB201611351D0 (en) | 2016-06-30 | 2016-06-30 | Benzolactam compounds |
| PCT/IB2016/001507 WO2017068412A1 (en) | 2015-10-21 | 2016-10-20 | Benzolactam compounds as protein kinase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021132047A Division JP7254127B2 (ja) | 2015-10-21 | 2021-08-13 | ベンゾラクタム化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018532737A JP2018532737A (ja) | 2018-11-08 |
| JP2018532737A5 true JP2018532737A5 (enExample) | 2019-11-28 |
| JP6931646B2 JP6931646B2 (ja) | 2021-09-08 |
Family
ID=57218943
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018519702A Active JP6931646B2 (ja) | 2015-10-21 | 2016-10-20 | ベンゾラクタム化合物 |
| JP2021132047A Active JP7254127B2 (ja) | 2015-10-21 | 2021-08-13 | ベンゾラクタム化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021132047A Active JP7254127B2 (ja) | 2015-10-21 | 2021-08-13 | ベンゾラクタム化合物 |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US10457669B2 (enExample) |
| EP (1) | EP3365334B1 (enExample) |
| JP (2) | JP6931646B2 (enExample) |
| KR (1) | KR102769567B1 (enExample) |
| CN (2) | CN108617166B (enExample) |
| AU (2) | AU2016341520C1 (enExample) |
| CA (1) | CA3001799A1 (enExample) |
| DK (1) | DK3365334T3 (enExample) |
| ES (1) | ES2989326T3 (enExample) |
| FI (1) | FI3365334T3 (enExample) |
| HR (1) | HRP20241210T1 (enExample) |
| HU (1) | HUE068392T2 (enExample) |
| IL (2) | IL291017B2 (enExample) |
| LT (1) | LT3365334T (enExample) |
| MA (1) | MA47013A (enExample) |
| MX (1) | MX382927B (enExample) |
| MY (1) | MY204050A (enExample) |
| PH (1) | PH12018500792A1 (enExample) |
| PL (1) | PL3365334T3 (enExample) |
| PT (1) | PT3365334T (enExample) |
| SA (1) | SA518391342B1 (enExample) |
| SG (1) | SG10201912959QA (enExample) |
| SI (1) | SI3365334T1 (enExample) |
| TW (1) | TWI747846B (enExample) |
| WO (1) | WO2017068412A1 (enExample) |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0811643D0 (en) | 2008-06-25 | 2008-07-30 | Cancer Rec Tech Ltd | New therapeutic agents |
| US9227978B2 (en) | 2013-03-15 | 2016-01-05 | Araxes Pharma Llc | Covalent inhibitors of Kras G12C |
| JO3805B1 (ar) | 2013-10-10 | 2021-01-31 | Araxes Pharma Llc | مثبطات كراس جي12سي |
| ES2898765T3 (es) | 2015-04-10 | 2022-03-08 | Araxes Pharma Llc | Compuestos de quinazolina sustituidos y métodos de uso de los mismos |
| ES2856880T3 (es) | 2015-04-15 | 2021-09-28 | Araxes Pharma Llc | Inhibidores tricíclicos condensados de KRAS y métodos de uso de los mismos |
| US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| US10689356B2 (en) | 2015-09-28 | 2020-06-23 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| EP3356353A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| WO2017058792A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| US10975071B2 (en) | 2015-09-28 | 2021-04-13 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| US10647703B2 (en) | 2015-09-28 | 2020-05-12 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| EP3356347A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| GB201517216D0 (en) | 2015-09-29 | 2015-11-11 | Cancer Res Technology Ltd And Astex Therapeutics Ltd | Pharmaceutical compounds |
| GB201517217D0 (en) | 2015-09-29 | 2015-11-11 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
| ES2989326T3 (es) | 2015-10-21 | 2024-11-26 | Otsuka Pharma Co Ltd | Compuestos de benzolactama como inhibidores de la proteína cinasa |
| US10414757B2 (en) | 2015-11-16 | 2019-09-17 | Araxes Pharma Llc | 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| CN108602802B (zh) * | 2016-07-26 | 2020-01-21 | 深圳市塔吉瑞生物医药有限公司 | 用于抑制蛋白酪氨酸激酶活性的氨基嘧啶类化合物 |
| US10865201B2 (en) * | 2016-09-12 | 2020-12-15 | Valo Health, Inc. | Bicyclic compounds useful as GPR120 modulators |
| CN110225752B (zh) | 2016-09-12 | 2023-05-05 | 整体健康 | 用作gpr120调节器的单环化合物 |
| WO2018064510A1 (en) | 2016-09-29 | 2018-04-05 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| US10377743B2 (en) * | 2016-10-07 | 2019-08-13 | Araxes Pharma Llc | Inhibitors of RAS and methods of use thereof |
| CN106588884B (zh) * | 2016-11-10 | 2019-04-09 | 浙江大学 | 2-多取代芳环-嘧啶类衍生物及制备和医药用途 |
| US11136308B2 (en) | 2017-01-26 | 2021-10-05 | Araxes Pharma Llc | Substituted quinazoline and quinazolinone compounds and methods of use thereof |
| EP3573954A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
| WO2018140599A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
| WO2018140600A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Fused hetero-hetero bicyclic compounds and methods of use thereof |
| EP3573971A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
| GB201704966D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| GB201704965D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| GB201706327D0 (en) * | 2017-04-20 | 2017-06-07 | Otsuka Pharma Co Ltd | A pharmaceutical compound |
| CN110869357A (zh) | 2017-05-25 | 2020-03-06 | 亚瑞克西斯制药公司 | 化合物及其用于治疗癌症的使用方法 |
| WO2018218069A1 (en) | 2017-05-25 | 2018-11-29 | Araxes Pharma Llc | Quinazoline derivatives as modulators of mutant kras, hras or nras |
| KR20200010306A (ko) | 2017-05-25 | 2020-01-30 | 아락세스 파마 엘엘씨 | Kras의 공유적 억제제 |
| BR112020005489A2 (pt) | 2017-09-22 | 2020-09-24 | Jubilant Epipad Llc, | composto da fórmula (i), composto de fórmula (ii), composto de fórmula (iii), processo de preparação de compostos de fórmula (i), processo de preparação de compostos de fórmula (ii), processo de preparação de compostos de fórmula (iii), composição farmacêutica, método para inibir uma ou mais famílias pad em uma célula, método para tratar uma afeção mediada por um ou mais pads, utilização do composto, método para o tratamento e/ou prevenção de uma afeção mediada por um ou mais distúrbios da família pad, método para o tratamento de artrite reumatoide e método de tratamento de câncer |
| CN111225915B (zh) | 2017-10-18 | 2023-03-07 | 朱比兰特埃皮帕德有限公司 | 作为pad抑制剂的咪唑并吡啶化合物 |
| EP3707135A1 (en) | 2017-11-06 | 2020-09-16 | Jubilant Prodel LLC | Pyrimidine derivatives as inhibitors of pd1/pd-l1 activation |
| IL274762B2 (en) | 2017-11-24 | 2023-10-01 | Jubilant Episcribe Llc | Novel heterocyclic compounds as prmt5 inhibitors |
| WO2019134662A1 (zh) * | 2018-01-03 | 2019-07-11 | 南京明德新药研发股份有限公司 | 作为csf-1r抑制剂的杂环化合物及其应用 |
| EP3765453A1 (en) | 2018-03-13 | 2021-01-20 | Jubilant Prodel LLC | Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation |
| CA3094719A1 (en) * | 2018-04-05 | 2019-10-10 | Tarveda Therapeutics, Inc. | Hsp90-targeting conjugates and formulations thereof |
| CN112638917B (zh) | 2018-05-22 | 2023-09-08 | 捷思英达控股有限公司 | 作为激酶抑制剂的杂环化合物、包括该杂环化合物的组合物、及其使用方法 |
| TWI707683B (zh) | 2018-06-13 | 2020-10-21 | 美商輝瑞股份有限公司 | Ｇｌｐ－１受體促效劑及其用途 |
| CA3107168A1 (en) | 2018-08-01 | 2020-02-06 | Araxes Pharma Llc | Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer |
| CN109377846B (zh) * | 2018-10-11 | 2020-12-08 | 内蒙古科技大学包头医学院 | 人体解剖学内脏标本的制作方法 |
| CN109608444B (zh) * | 2018-11-27 | 2022-02-11 | 中国药科大学 | 含异吲哚啉酮的erk抑制剂及其制备方法与用途 |
| WO2020127208A2 (en) * | 2018-12-18 | 2020-06-25 | Astrazeneca Ab | Pharmaceutical process and intermediates |
| CN111057048B (zh) * | 2019-01-30 | 2022-03-18 | 上海凌达生物医药有限公司 | 一类氨基吡嗪/吡啶类化合物、制备方法和用途 |
| EP3931188B1 (en) * | 2019-02-26 | 2023-08-30 | Boehringer Ingelheim International GmbH | New isoindolinone substituted indoles and derivatives as ras inhibitors |
| CN113710246A (zh) * | 2019-04-03 | 2021-11-26 | 塔弗达治疗有限公司 | Hsp90结合缀合物及其制剂 |
| JP2022534224A (ja) * | 2019-05-24 | 2022-07-28 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 置換縮合二環式誘導体、その調製方法、および医薬におけるその適用 |
| SG11202110085TA (en) * | 2019-05-31 | 2021-10-28 | Sichuan Haisco Pharmaceutical Co Ltd | Btk inhibitor ring derivative, preparation method therefor and pharmaceutical application thereof |
| CN114206852A (zh) | 2019-08-09 | 2022-03-18 | 卡尔维斯塔制药有限公司 | 血浆激肽释放酶抑制剂 |
| WO2021055728A1 (en) | 2019-09-18 | 2021-03-25 | Merck Sharp & Dohme Corp. | Small molecule inhibitors of kras g12c mutant |
| CN112574207B (zh) * | 2019-09-30 | 2023-04-11 | 南京药石科技股份有限公司 | Erk1/2蛋白激酶抑制剂及其用途 |
| IL291783A (en) * | 2019-10-02 | 2022-06-01 | Domain Therapeutics | ep4 prostaglandin e2 receptor antagonists |
| CR20220230A (es) | 2019-10-28 | 2022-06-15 | Merck Sharp & Dohme | Inhibidores de pequeñas moléculas de mutante g12c de kras |
| WO2021085653A1 (en) | 2019-10-31 | 2021-05-06 | Taiho Pharmaceutical Co., Ltd. | 4-aminobut-2-enamide derivatives and salts thereof |
| WO2021106231A1 (en) | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
| EP4071155A4 (en) * | 2019-12-06 | 2024-01-17 | D3 Bio (Wuxi) Co., Ltd. | THIAZOLOLACTAM COMPOUND USED AS ERK INHIBITOR AND USE THEREOF |
| US20230174518A1 (en) | 2020-04-24 | 2023-06-08 | Taiho Pharmaceutical Co., Ltd. | Kras g12d protein inhibitors |
| WO2021215545A1 (en) | 2020-04-24 | 2021-10-28 | Taiho Pharmaceutical Co., Ltd. | Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c |
| CA3177298C (en) * | 2020-04-30 | 2023-11-21 | Xile LIU | Compounds containing benzosultam as erk inhibitors |
| WO2021224818A1 (en) * | 2020-05-08 | 2021-11-11 | Pfizer Inc. | Isoindolone compounds as hpk1 inhibitors |
| CA3190001A1 (en) * | 2020-08-21 | 2022-02-24 | Shanghai Ringene Biopharma Co., Ltd. | Aromatic ring-lactam compound, preparation method therefor and use thereof |
| EP4249481A4 (en) * | 2020-11-20 | 2024-10-30 | Hefei Institutes of Physical Science, Chinese Academy of Sciences | DIHYDROISOQUINOLINONE AND ISOINDOLINONE DERIVATIVES AND USES THEREOF |
| JP2024515964A (ja) * | 2021-04-26 | 2024-04-11 | オハイオ ステート イノベーション ファウンデーション | 脂質ナノ材料及びその使用 |
| CN117769554A (zh) | 2021-05-28 | 2024-03-26 | 大鹏药品工业株式会社 | Kras突变蛋白的小分子抑制剂 |
| TWI809904B (zh) * | 2021-06-02 | 2023-07-21 | 大陸商南京明德新藥研發有限公司 | 一種二甲基取代的噻唑並吡咯酮類化合物的晶型及其製備方法 |
| US20240287051A1 (en) * | 2021-06-11 | 2024-08-29 | Otsuka Pharmaceutical Co., Ltd. | Process for preparing an erk inhibitor |
| WO2023039548A1 (en) * | 2021-09-10 | 2023-03-16 | Fred Hutchinson Cancer Center | Kinase inhibitors for the treatment of prostate cancer |
| WO2023076305A1 (en) | 2021-10-26 | 2023-05-04 | Otsuka Pharmaceutical Co., Ltd. | Compositions comprising an erk inhibitor |
| CA3267147A1 (en) | 2022-09-13 | 2024-03-21 | Amphista Therapeutics Limited | COMPOUNDS FOR THE TARGETED DEGRADATION OF A PROTEIN |
| US20260008788A1 (en) * | 2022-09-29 | 2026-01-08 | Suzhou Ark Biopharmaceutical Co., Ltd. | Aza-fused ring compound, preparation method therefor, and use thereof in medicine |
| CN119790049A (zh) * | 2022-09-30 | 2025-04-08 | 楚浦创制（武汉）医药科技有限公司 | 2-氨基嘧啶类化合物及其应用、药用组合物 |
| WO2024220866A1 (en) * | 2023-04-19 | 2024-10-24 | Accutar Biotechnology Inc. | Novel aminopyrimidine derivatives as cyclin-dependent kinase inhibitors |
| TW202535891A (zh) | 2023-10-20 | 2025-09-16 | 美商默沙東有限責任公司 | Ｋｒａｓ蛋白之小分子抑制劑 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5629327A (en) | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
| US5463063A (en) | 1993-07-02 | 1995-10-31 | Celgene Corporation | Ring closure of N-phthaloylglutamines |
| US5958934A (en) | 1996-05-23 | 1999-09-28 | Syntex (U.S.A.) Inc. | Aryl pyrimidine derivatives and uses thereof |
| CA2333927A1 (en) | 1998-04-01 | 1999-10-07 | Dupont Pharmaceuticals Company | Pyrimidines and triazines as integrin antagonists |
| HUP0402352A2 (hu) | 2001-06-19 | 2005-02-28 | Bristol-Myers Squibb Co. | Foszfodiészteráz (PDE) 7 inhibitorként alkalmazható pirimidinszármazékok és ezeket tartalmazó gyógyszerkészítmények |
| ATE372324T1 (de) | 2003-04-30 | 2007-09-15 | Inst For Pharm Discovery Inc | Substituierte heteroarylverbindungen als inhibitoren von proteintyrosinphosphatasen |
| CA2536954C (en) | 2003-08-29 | 2012-11-27 | Exelixis, Inc. | C-kit modulators and methods of use |
| US7504401B2 (en) | 2003-08-29 | 2009-03-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
| DK3305776T3 (da) | 2004-05-14 | 2019-12-09 | Vertex Pharma | Pyrrol-forbindelser som inhibitorer af erk-protein-kinaser og farmaceutiske sammensætninger, der indeholder disse forbindelser |
| US20060235036A1 (en) | 2005-04-15 | 2006-10-19 | Doherty Elizabeth M | Vanilloid receptor ligands and their use in treatments |
| CA2633023C (en) | 2005-12-13 | 2015-11-24 | Schering Corporation | Polycyclic indazole derivatives that are erk inhibitors |
| US20080280891A1 (en) | 2006-06-27 | 2008-11-13 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
| CA2654670A1 (en) | 2006-07-06 | 2008-01-10 | Boehringer Ingelheim International Gmbh | New compounds |
| WO2008008059A1 (en) | 2006-07-12 | 2008-01-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents ans uses thereof |
| WO2008124085A2 (en) | 2007-04-03 | 2008-10-16 | Exelixis, Inc. | Methods of using combinations of mek and jak-2 inhibitors |
| WO2009017838A2 (en) | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinations of jak-2 inhibitors and other agents |
| WO2009039635A1 (en) | 2007-09-24 | 2009-04-02 | Painceptor Pharma Corporation | Methods of modulating neurotrophin-mediated activity |
| US20100267712A1 (en) * | 2007-09-27 | 2010-10-21 | The United States of America, as represented by the Secretary, Department of Health and | Isoindoline compounds for the treatment of spinal muscular atrophy and other uses |
| PT2231640E (pt) | 2008-01-24 | 2012-08-23 | Merck Patent Gmbh | Derivados beta-aminoácido para o tratamento de diabetes |
| US8338439B2 (en) * | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| SG10201510696RA (en) * | 2008-06-27 | 2016-01-28 | Celgene Avilomics Res Inc | Heteroaryl compounds and uses thereof |
| GB0815369D0 (en) | 2008-08-22 | 2008-10-01 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
| TWI453207B (zh) * | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶，其組合物及使用其之治療方法 |
| GB0821307D0 (en) | 2008-11-21 | 2008-12-31 | Summit Corp Plc | Compounds for treatment of duchenne muscular dystrophy |
| BRPI0922565A2 (pt) * | 2008-12-19 | 2015-12-15 | Bristol Myers Squibb Co | compostos de carbazol carboxamida úteis como inibidores de cinase |
| EP2429987A4 (en) | 2009-05-15 | 2012-10-03 | Korea Res Inst Chem Tech | AMIDE COMPOUND, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME |
| WO2010151747A1 (en) | 2009-06-26 | 2010-12-29 | Cystic Fibrosis Foundation Therapeutics, Inc. | Pyrimine compounds and methods of making and using same |
| WO2011008931A2 (en) | 2009-07-15 | 2011-01-20 | Cystic Fibrosis Foundation Therapeutics, Inc. | Arylpyrimidine compounds and combination therapy comprising same for treating cystic fibrosis & related disorders |
| NZ600954A (en) | 2009-12-22 | 2013-11-29 | Isoindolinone inhibitors of phosphatidylinositol 3-kinase | |
| WO2011075784A1 (en) * | 2009-12-23 | 2011-06-30 | Peter Maccallum Cancer Institute | Compounds, preparations and uses thereof |
| RU2012132682A (ru) | 2009-12-31 | 2014-02-10 | Пирамал Энтерпрайзис Лимитед | Ингибиторы диацилглицерин ацилтрансферазы |
| JP5944823B2 (ja) | 2010-07-02 | 2016-07-05 | あすか製薬株式会社 | 複素環化合物及びｐ２７Ｋｉｐ１分解阻害剤 |
| CA2806341C (en) | 2010-07-29 | 2020-03-24 | Rigel Pharmaceuticals, Inc. | Ampk-activating heterocyclic compounds and methods for using the same |
| US9938269B2 (en) | 2011-06-30 | 2018-04-10 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
| DK3321262T3 (da) | 2012-03-01 | 2021-01-25 | Array Biopharma Inc | Serin-/threoninkinasehæmmere |
| IN2014KN02601A (enExample) * | 2012-04-24 | 2015-05-08 | Vertex Pharma | |
| CN104583195B (zh) | 2012-09-12 | 2018-08-17 | 山东亨利医药科技有限责任公司 | 作为酪氨酸激酶抑制剂的含氮杂芳环衍生物 |
| US20150272939A1 (en) | 2012-10-02 | 2015-10-01 | Yale University | Identification of Small Molecule Inhibitors of Jumonji AT-Rich Interactive Domain 1A (JARID1A) and 1B (JARID1B) Histone Demethylase |
| IL291945B2 (en) | 2012-11-01 | 2025-11-01 | Infinity Pharmaceuticals Inc | Treatment of cancers using pi3 kinase isoform modulators |
| US9561228B2 (en) | 2013-02-08 | 2017-02-07 | Celgene Avilomics Research, Inc. | ERK inhibitors and uses thereof |
| US20140357636A1 (en) | 2013-02-21 | 2014-12-04 | Wayne Rothbaum | Treatment of Skeletal-Related Disorders |
| WO2015030847A1 (en) | 2013-08-30 | 2015-03-05 | Ptc Therapeutics, Inc. | Substituted pyrimidine bmi-1 inhibitors |
| WO2015048547A2 (en) | 2013-09-26 | 2015-04-02 | Rigel Pharmaceuticals, Inc. | Methods for using and biomarkers for ampk-activating compounds |
| TN2016000270A1 (en) * | 2014-01-14 | 2017-10-06 | Millennium Pharm Inc | Heteroaryls and uses thereof. |
| LT3126352T (lt) | 2014-04-04 | 2019-01-10 | Syros Pharmaceuticals, Inc. | Nuo ciklino priklausomos kinazės 7 (cdk7) inhibitoriai |
| US11311541B2 (en) | 2014-04-09 | 2022-04-26 | Kadmon Corporation, Llc | Treatment of GVHD |
| WO2016025649A1 (en) | 2014-08-13 | 2016-02-18 | Celgene Avilomics Research, Inc. | Combinations of an erk inhibitor and a dot1l inhibitor and related methods |
| TWI704151B (zh) | 2014-12-22 | 2020-09-11 | 美商美國禮來大藥廠 | Ｅｒｋ抑制劑 |
| WO2016162325A1 (en) | 2015-04-07 | 2016-10-13 | Astrazeneca Ab | Substituted 3,4-dihydropyrrolo[1,2-a]pyrazin-1 (2h)-one derivatives as kinase inhibitors |
| PL3307727T3 (pl) | 2015-06-15 | 2024-07-08 | Asana Biosciences, Llc | Heterocykliczne inhibitory erk1 i erk2 oraz ich zastosowanie w leczeniu nowotworów |
| CA2987914C (en) * | 2015-06-30 | 2022-09-13 | Dana-Farber Cancer Institute, Inc. | Inhibitors of egfr and methods of use thereof |
| ES2989326T3 (es) | 2015-10-21 | 2024-11-26 | Otsuka Pharma Co Ltd | Compuestos de benzolactama como inhibidores de la proteína cinasa |
| WO2017080979A1 (en) | 2015-11-09 | 2017-05-18 | Astrazeneca Ab | Dihydroimidazopyrazinone derivatives useful in the treatment of cancer |
| CN108602802B (zh) | 2016-07-26 | 2020-01-21 | 深圳市塔吉瑞生物医药有限公司 | 用于抑制蛋白酪氨酸激酶活性的氨基嘧啶类化合物 |
| GB201706327D0 (en) | 2017-04-20 | 2017-06-07 | Otsuka Pharma Co Ltd | A pharmaceutical compound |
| US20240287051A1 (en) * | 2021-06-11 | 2024-08-29 | Otsuka Pharmaceutical Co., Ltd. | Process for preparing an erk inhibitor |
| WO2023076305A1 (en) * | 2021-10-26 | 2023-05-04 | Otsuka Pharmaceutical Co., Ltd. | Compositions comprising an erk inhibitor |
-
2016
- 2016-10-20 ES ES16788794T patent/ES2989326T3/es active Active
- 2016-10-20 MX MX2018004643A patent/MX382927B/es unknown
- 2016-10-20 SG SG10201912959QA patent/SG10201912959QA/en unknown
- 2016-10-20 HR HRP20241210TT patent/HRP20241210T1/hr unknown
- 2016-10-20 CA CA3001799A patent/CA3001799A1/en active Pending
- 2016-10-20 MY MYPI2018701450A patent/MY204050A/en unknown
- 2016-10-20 JP JP2018519702A patent/JP6931646B2/ja active Active
- 2016-10-20 IL IL291017A patent/IL291017B2/en unknown
- 2016-10-20 HU HUE16788794A patent/HUE068392T2/hu unknown
- 2016-10-20 PL PL16788794.2T patent/PL3365334T3/pl unknown
- 2016-10-20 US US15/767,775 patent/US10457669B2/en active Active
- 2016-10-20 DK DK16788794.2T patent/DK3365334T3/da active
- 2016-10-20 MA MA047013A patent/MA47013A/fr unknown
- 2016-10-20 AU AU2016341520A patent/AU2016341520C1/en active Active
- 2016-10-20 CN CN201680061146.4A patent/CN108617166B/zh active Active
- 2016-10-20 SI SI201631846T patent/SI3365334T1/sl unknown
- 2016-10-20 EP EP16788794.2A patent/EP3365334B1/en active Active
- 2016-10-20 WO PCT/IB2016/001507 patent/WO2017068412A1/en not_active Ceased
- 2016-10-20 PT PT167887942T patent/PT3365334T/pt unknown
- 2016-10-20 FI FIEP16788794.2T patent/FI3365334T3/fi active
- 2016-10-20 LT LTEPPCT/IB2016/001507T patent/LT3365334T/lt unknown
- 2016-10-20 TW TW105133824A patent/TWI747846B/zh active
- 2016-10-20 KR KR1020187013571A patent/KR102769567B1/ko active Active
- 2016-10-20 CN CN202210512050.2A patent/CN114948963B/zh active Active
-
2018
- 2018-04-12 SA SA518391342A patent/SA518391342B1/ar unknown
- 2018-04-12 PH PH12018500792A patent/PH12018500792A1/en unknown
- 2018-04-12 IL IL258662A patent/IL258662B/en unknown
-
2019
- 2019-08-15 US US16/541,863 patent/US11001575B1/en active Active
-
2021
- 2021-02-12 AU AU2021200951A patent/AU2021200951B2/en active Active
- 2021-04-07 US US17/224,733 patent/US11939321B2/en active Active
- 2021-08-13 JP JP2021132047A patent/JP7254127B2/ja active Active
-
2023
- 2023-10-19 US US18/490,403 patent/US20240368136A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018532737A5 (enExample) | ||
| JP5749341B2 (ja) | ピロロピリミジン化合物およびその使用 | |
| JP6934261B2 (ja) | Ｎ−（アザアリール）シクロラクタム−１−カルボキサミド誘導体、その製造方法および応用 | |
| AU2014351413B2 (en) | Pyrrolopyrrolone derivatives and their use as BET inhibitors | |
| RU2560153C2 (ru) | Триазолпиридиновые соединения, ингибирующие jak, и способы | |
| WO2012022045A1 (en) | Pyrrolopyrimidine compounds and uses thereof | |
| RU2014130125A (ru) | Новые пиррольные соединения, способ их получения и фармацевтические композиции, содержащие их | |
| BR112012011287B1 (pt) | Compostos inibidores de cinase derivados de pirolopirimidina, sua formulação farmacêutica e seus usos | |
| BR112017007769B1 (pt) | Compostos derivados de aminopirimidina, composição farmacêutica que compreende os ditos compostos e uso terapêutico dos mesmos | |
| JP2017031207A (ja) | 置換６，６−縮合窒素複素環化合物及びその使用 | |
| WO2018045957A1 (zh) | 一种cdk4/6抑制剂及其制备方法和应用 | |
| CN102459187A (zh) | Janus激酶抑制化合物和方法 | |
| RU2014130129A (ru) | Новые фосфатные соединения, способ их получения и фармацевтические композиции, содержащие их | |
| JP7782035B2 (ja) | Ｊａｋ２阻害剤としての６－ヘテロアリールオキシベンゾイミダゾール及びアザベンゾイミダゾール | |
| EP4237418B1 (en) | Pyrimidine compounds, compositions, and medicinal applications thereof | |
| WO2022246459A1 (en) | Combination therapy | |
| EP4608820A1 (en) | Heterocyclic compounds capable of activating sting | |
| CN114437074A (zh) | 一种化合物、含该化合物的药物组合物及其用途 | |
| CN116323582B (zh) | 杂芳环类化合物及其用途 | |
| HK40129802A (zh) | 杂芳基杂环化合物及其用途 | |
| HK40095637A (zh) | 杂芳环类化合物及其用途 | |
| HK40121672A (zh) | 杂芳基杂环化合物及其用途 | |
| HK40094658A (zh) | 杂芳基杂环化合物及其用途 | |
| HK40094658B (zh) | 杂芳基杂环化合物及其用途 | |
| HK40074266B (zh) | 杂芳基杂环化合物及其用途 |